Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality

Abstract

Background: The relationship between systolic blood pressure (SBP) reduction and the risk of cardiovascular disease (CVD) and mortality has garnered significant attention in recent years, as evidenced by a series of studies that illuminate various aspects of this critical health issue. Literature Review: The initial study by (Dinesh Jani et al., 2016) highlights the dual role of elevated SBP and depressive symptoms as independent predictors of major adverse cardiovascular events (MACE) in patients with cardiometabolic disease. Further emphasizing the need for careful management, (Thomas Manapurathe et al., 2019) examined the implications of hypertension in patients with peripheral artery disease (PAD), demonstrating that antihypertensive treatment could reduce cardiovascular events significantly. The systematic review by (Baffour-Awuah et al., 2020) further supports the argument for lower BP treatment targets in older adults, linking lower SBP levels with reduced rates of major cardiovascular events and mortality. In recent contributions, (Nawata, 2022) reinforced the connection between SBP reduction and lower cardiovascular risk, while (Kodela et al., 2023) highlighted the effectiveness of non-pharmacological interventions in managing hypertension. These lifestyle modifications not only aid in controlling blood pressure but also reduce reliance on medications, thus improving overall health outcomes.  Conclusion: In conclusion, the literature collectively emphasizes the necessity for a nuanced approach to SBP management, considering individual patient profiles and the potential risks associated with both high and low blood pressure levels. The evidence supports the assertion that effective SBP reduction is pivotal in lowering the risk of cardiovascular disease and mortality, necessitating tailored management strategies that integrate both pharmacological and lifestyle interventions.